IBA SA: data concerning transparency
06 Décembre 2018 - 6:00PM
IBA SA: data concerning transparency
IBA – DATA CONCERNING
TRANSPARENCYHeading II of the law of May 2, 2007
and the Royal Decree of February 14, 2008
Louvain-la-Neuve, Belgium, December 3, 2018 -
IBA (Ion Beam Applications SA), the world’s leading provider of
proton therapy solutions for the treatment of cancer, communicates
today the basic and additional data as per Article 15 §1 al.1 of
the Transparency Law, following its capital increase (further to
exercises of stock options) dated November 28, 2018.
Communication of the basic data as per Article 15 §1 al.1 of the
Law
- Total capital: EUR 42 278 193.63
- Total number of securities conferring the voting right: 30 122
528
- Total number of voting rights (= the denominator): 30 122
528
- Total number of securities conferring the voting right, by
category: N/A
- Total number of voting rights, by category: N/A
Communication of the additional data as per Article 15 §1 al.2
of the Law
- Total number of convertible bonds conferring the voting right:
0
- Total number of rights, materialized or not by certificates,
giving the right to subscribe to newly issued securities conferring
the voting right (e.g. warrants): 198 500
- Total number of voting rights which would result from the
exercise of these conversion or subscription rights: 198 500
- Total number of shares without voting right: 0
Statutory thresholds as per Article 18 of the Law
The applicable thresholds as follows: three percent, five
percent, ten percent, fifteen percent and so on by brackets of five
percent
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA’s
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room solutions. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,500 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can
be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com
- 20181128evolutionofthebasicdataEN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024